KPTI
Karyopharm Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.35
−11.30%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.40
From 52W high−96.76%
Volume1.25M
Market cap$7.85M
P/E (TTM)—
P/S (TTM)0.1x
Div yield—
Key dataOct 19, 2026
Open
$0.40
From 52W high
−96.76%
Volume
1.25M
Market cap
$7.85M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
P/E (TTM)
—
RSI (14)
18.1
MomentumView details →
1D Return
−11.30%
YTD Return
−95.26%
SummaryUpdated Jun 1, 2026
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage pharmaceutical company founded in 2008 and headquartered in Newton, Massachusetts. The company went public in 2013 and specializes in developing and commercializing a novel class of cancer drugs called Selective Inhibitor of Nuclear Export (SINE) compounds. Karyopharm's lead product, XPOVIO (selinexor), is currently approved for multiple myeloma and diffuse large B-cell lymphoma, with the company advancing an ambitious pipeline of three Phase 3 trials targeting additional cancer indications including myelofibrosis and endometrial cancer.
Similar companies
Latest newsMore news →
Karyopharm pushed off a debt payment, buying an extra month to negotiate with creditors or pursue a deal.26d agoKaryopharm Therapeutics submitted a supplemental New Drug Application to the U.S. FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis.50d ago